ArticleFrontiers in endocrinology2026
Elevated GDF15 in ocular fluids of patients with proliferative diabetic retinopathy.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objective: Growth differentiation factor 15 (GDF15) is a multifunctional stress-responsive cytokine widely involved in inflammation, oxidative stress, and microvascular injury. Its expression profile in the local intraocular microenvironment of patients with proliferative diabetic retinopathy (PDR) remains unclear. This study aimed to detect GDF15 levels in aqueous humor (AH) and vitreous humor (VH) of PDR patients, analyze its differential expression, and provide preliminary evidence for understanding the intraocular expression pattern of GDF15 in PDR. Methods: GDF15 levels were quantified by enzyme-linked immunosorbent assay (ELISA) in AH and VH samples from PDR patients and compared with those in AH from age-related cataract patients and VH from patients with macular hole or epiretinal membrane. Results: GDF15 levels in AH of PDR patients were significantly higher than those in cataract controls; GDF15 levels in VH of PDR patients were markedly higher than those in macular hole/epiretinal membrane controls. An exploratory comparison between AH and VH samples from independent PDR patient cohorts showed higher GDF15 levels in VH than in AH. Conclusion: GDF15 expression is significantly upregulated in AH and VH of PDR patients, with a potential difference between ocular fluid compartments, suggesting an association between intraocular GDF15 upregulation and PDR. These findings provide preliminary evidence for further investigation of GDF15-related inflammatory and stress responses in the local intraocular microenvironment of PDR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.